Biotech firms Cara Therapeutics and SpringWorks Therapeutics have announced licensing and acquisition deals that could be worth several hundred million dollars.
Cara signed a deal with Vifor Pharma for the commercialization across the entire U.S. dialysis market of its Korsuva injection, which treats the itch condition known as pruritus in chronic kidney disease patients.
SpringWorks is selling its fatty acid amide hydrolase inhibitor program including PF-04457845 for the treatment of post-traumatic stress disorder and associated symptoms to the Irish-based Jazz Pharmaceuticals.
article in ctpost
article in Westchester & Fairfield Business Journals